Naijie Jing

Nanjing Medical University — China

Medicine · Health Sciences

23h-index1.9kcitations56works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cytokine Signaling Pathways and Interactions(24), DNA and Nucleic Acid Chemistry(11), Cancer Mechanisms and Therapy(10), HIV/AIDS drug development and treatment(8), PI3K/AKT/mTOR signaling in cancer(8)

Publications56 total

<scp>25HC</scp> Depleted <scp>PMs</scp> ‐Accessible Cholesterol to Restrict <scp>SFTSV</scp> Entry and Infectious‐ <scp>EVs</scp> Mediated Infection
The FASEB Journal·2025
A Retrospective Study Examined the Impact of the IKAP Nursing Model on the Self-Efficacy and Quality of Life of Colorectal Cancer Patients with Permanent Stomas
SAGE Open Nursing·2025Open Access
Research and application of supramolecular gel plugging agent in abnormal pressure reservoir
Journal of Physics Conference Series·2021Open Access
Development of responsive well plugging material in carbonate reservoir
Journal of Physics Conference Series·2021· 1 citedOpen Access
A perylene derivative regulates HIF-1α and Stat3 signaling pathways
Bioorganic & Medicinal Chemistry·2013· 11 citedOpen Access
Nanoparticle delivery of inhibitory signal transducer and activator of transcription 3 G-quartet oligonucleotides blocks tumor growth in<i>HMGA1</i>transgenic model of T-cell leukemia
Leukemia & lymphoma/Leukemia and lymphoma·2013· 13 citedOpen Access
Development of a Combination Therapy for Prostate Cancer by Targeting Stat3 and HIF-1alpha
2013
Signal Transducer and Activator of Transcription 3 (STAT3) Regulates Collagen-Induced Platelet Aggregation Independently of Its Transcription Factor Activity
Circulation·2012· 72 citedOpen Access
Development of a Combination Therapy for Prostate Cancer by Targeting Stat3 and HIF-1alpha
2012
Rational Design of DNA Anticancer Agent That Targets Signal Transducer and Activator of Transcription 3 (Stat3) for Cancer Therapy
2011
Abstract A123: TEL is a dual anticancer agent that targets Stat3 and HIF-1α.
Molecular Cancer Therapeutics·2011· 1 cited
Development of a Combination Therapy for Prostate Cancer by Targeting Stat3 and HIF-1alpha
2011· 1 cited
Combined treatment targeting HIF‐1α and Stat3 is a potent strategy for prostate cancer therapy
The Prostate·2011· 32 cited
103 Combination treatment of targeting Stat3 and HIF-1alpha is a potent strategy for prostate cancer therapy
European Journal of Cancer Supplements·2010· 3 cited
G-rich Oligonucleotides Inhibit HIF-1α and HIF-2α and Block Tumor Growth
Molecular Therapy·2009· 24 citedOpen Access
A G-quartet oligonucleotide blocks glycoprotein Ib-mediated platelet adhesion and aggregation under flow conditions
Thrombosis and Haemostasis·2009· 3 cited
T40214/PEI complex: A potent therapeutics for prostate cancer that targets STAT3 signaling
The Prostate·2008· 33 citedOpen Access
G-Quartet Oligonucleotide T70923 Blocks GP Ib-VWF Mediated Platelet Aggregation under Static and Flow Conditions.
Blood·2007
JG-ODNs, novel G-quartet oligonucleotides, inhibit HIF-1a and HIF-2a activity and suppress growth of pancreatic and prostate tumors
Molecular Cancer Therapeutics·2007
Computational study on mechanism of G-quartet oligonucleotide T40214 selectively targeting Stat3
Journal of Computer-Aided Molecular Design·2007· 23 cited
page 1 of 3Next →

Frequent Co-authors

David J. Tweardy(13), Yongli Guan(9), Qiqing Zhu(8), Dan W. Urry(7), Michael E. Hogan(5), Yves Pommier(4), Priya Weerasinghe(4), Kavitha Ramasamy Reddy(4), Robert F. Rando(3), Yidong Li(3), Wei Sha(3), Christophe Marchand(3), Xuejun Xu(3), Zhou Zhou(3), Luke A. Pallansch(3), Huang Shao(3), Yifei Li(3), Josef T. Prchal(3), Weijun Xiong(2), Ping Yuan(2)